A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab

• Published in: Gan to kagaku ryoho Vol. 33; no. 9; p. 1305
• Main Authors: Nakajima, Hiroo, Mizuta, Naruhiko, Mizuta, Mitsuhiko, Nakatsukasa, Katsuhiko, Kobayashi, Aya, Hachimine, Yasushi, Sakaguchi, Koichi, Fujiwara, Ikuya, Sawai, Kiyoshi
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.09.2006
• Subjects: Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Carcinoma, Ductal, Breast - drug therapy; Carcinoma, Ductal, Breast - metabolism; Carcinoma, Ductal, Breast - secondary; Carcinoma, Ductal, Breast - surgery; Drug Administration Schedule; Drug Combinations; Female; Humans; Lymph Nodes - pathology; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Oxonic Acid - administration & dosage; Receptor, ErbB-2 - biosynthesis; Tegafur - administration & dosage; Trastuzumab
• ISSN: 0385-0684

We experienced a case of multi-drug resistant recurrent breast cancer with multiple bone metastases achieving a significant improvement by TS-1 and trastuzumab. The prior treatments including taxane or vinorelbine and trastuzumab were changed in the regimen to TS-1 and trastuzumab because of the progressive disease. TS-1 was administered orally at 100 mg/day everyday for 2 weeks, followed by a 1-week rest interval as 1 cycle, and trastuzumab was injected at 2 mg/kg/week for 4 weeks, followed by a 1-week rest interval as 1 cycle. After 3 cycles of the treatment, the level of tumor markers and tumor sizes of bone metastases became reduced. In conclusion, the combination treatment of TS-1 and trastuzumab is thought to be effective for multi-drug resistant recurrent breast cancer.